|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02126 JW THERAP-B
Nominal 
1.960 -0.060 (-2.970%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 111,353 | 4.708% | 283,653 | 158,218 | 173,856 | 145,702 |
| Cost of Sales | (53,647) | 30.120% | (110,571) | (80,902) | (85,637) | (86,946) |
| Gross Profit | 57,706 | -11.381% | 173,082 | 77,316 | 88,219 | 58,756 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (50,426) | -81.133% | (552,225) | (590,624) | (767,996) | (846,135) | |
| Taxation | 0 | -- | (3,067) | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (50,426) | -81.133% | (555,292) | (590,624) | (767,996) | (846,135) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (231) | -96.260% | 9,521 | (16,211) | (21,611) | (9,748) |
| Depreciation & Amortisation | 31,115 | -2.613% | 64,089 | 77,244 | 78,673 | 84,810 |
| Directors' Emoluments | 797 | -3.860% | 5,286 | 24,680 | 22,833 | 32,981 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -12.000 | -81.250% | -134.000 | -143.000 | -187.000 | -206.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.185) | (0.806) | (0.968) | (1.309) |
| NBV per share ($) | 1.086 | -- | 1.336 | 2.814 | 4.083 | 5.728 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -50,426 |
| %Change | -81.133% |
| EPS / (LPS) | RMB -0.120 |
| NBV Per Share (¥) | RMB 1.086 |